YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer

Globally, lung cancer stands as the foremost cause of cancer-related mortality. Among its subtypes, small cell lung cancer (SCLC) represents an exceptionally aggressive malignancy, accounting for approximately 15-20% of all lung cancer cases. Over two-thirds of SCLC patients are diagnosed at an extensive stage, facing a median survival of only 7-12 months, a 2-year survival rate below 5%, and a dismal 5-year survival rate of 2%, underscoring its poor prognosis and high mortality. First-line treatment for extensive-stage SCLC typically involves comprehensive therapy centered on chemotherapy, of

Trial Details

NCT ID
NCT07390565
Phase
NA
Sponsor
LI FENG
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Yishen Qutong Granules
  • Yishen Qutong Simulant Granules
Locations (sample)
  • Beijing, Chaoyang, China|39.9075,116.39723

Key Eligibility Criteria

  • Meets Western medical diagnostic criteria for extensive-stage small cell lung cancer and Chinese medicine diagnostic criteria for kidney deficiency…
  • Newly diagnosed extensive-stage small cell lung cancer patients who have not previously received Western medical antineoplastic therapy, with evalu…
  • Intended to receive ≥2 cycles of first-line immunotherapy plus platinum-based chemotherapy plus etoposide;
  • No concurrent or prior history of other primary malignancies;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →